beta

FLXN

Flexion Therapeutics Inc.

Flxn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 02-27-2019 after market close 11-07-2018 after market close 08-07-2018 after market close 05-08-2018 after market close 03-08-2018 after market close 11-06-2017 after market close 08-08-2017 after market close 05-04-2017 after market close
Actual EPS -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.07 -1.15 -1.16 -1.1 -1.38 -1.07 -0.91 -0.75
Consensus EPS -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.22 -1.35 -1.12 -0.98 -0.8 -0.73
Estimated EPS -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.24 -1.22 -1.35 -1.12 -0.98 -0.8 -0.73
Number of Estimates 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 3 4 3 4
EPS Surprise $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.17 $0.09 $0.06 $0.25 -$0.26 -$0.09 -$0.11 -$0.02

Stats

Summary

Flexion Therapeutics Inc is a development stage specialty pharmaceutical company. The Company is engaged in the development and commercialization of novel, long-acting, injectable pain therapies including; anti-inflammatory and analgesic therapies.

Market Cap: 886 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.flexiontherapeutics.com

Shares Outstanding: 37.5 Million

Float: 37.4 Million

Dividend: 0.0 (0.0%)

Beta: 0.915089

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 9.96 Million

Ethical Flags

Animal testing

Longest drawdown: 603 trading days

From: 2017-10-06 To: 2019-09-13

Lowest Point:

Flexion Therapeutics nabs new patent in U.S.

via: SeekingAlpha at 2019-06-05 04:44:24:000

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics nabs new patent in U.S.

via: SeekingAlpha at 2019-06-05 04:44:24:000

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics nabs new patent in U.S.

via: SeekingAlpha at 2019-06-05 04:44:24:000

The USPTO has issued Flexion Therapeutics' (NASDAQ: FLXN ) patent number 10,301,645 for FX201, the company's gene therapy product candidate to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the j… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

Flexion Therapeutics: The Bottom Could Now Be In

via: SeekingAlpha at 2019-05-15 08:09:01:000

"How easy it is for so many of us today to be undoubtedly full of information yet fully deprived of accurate information." - Criss Jami One biotech stock that has held up very well during the recent turbulence of the market is Flexion Therapeutics ( FLXN ) . The stock was up over 15% last… read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion up 14% premarket on Zilretta ramp

via: SeekingAlpha at 2019-05-09 05:03:42:000

Flexion Therapeutics (NASDAQ: FLXN ) is up 14% premarket on light volume on the heels of its Q1 report released after the close yesterday. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Sarepta a "Fresh Pick" at Baird in premarket analyst action

via: SeekingAlpha at 2019-05-09 04:16:53:000

ElectroCore (NASDAQ: ECOR ) initiated with Outperform rating and $19 (222% upside) at Noble Capital. More news on: electroCore, Inc., Sarepta Therapeutics, Inc., Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Sarepta a "Fresh Pick" at Baird in premarket analyst action

via: SeekingAlpha at 2019-05-09 04:16:53:000

ElectroCore (NASDAQ: ECOR ) initiated with Outperform rating and $19 (222% upside) at Noble Capital. More news on: electroCore, Inc., Sarepta Therapeutics, Inc., Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Sarepta a "Fresh Pick" at Baird in premarket analyst action

via: SeekingAlpha at 2019-05-09 04:16:53:000

ElectroCore (NASDAQ: ECOR ) initiated with Outperform rating and $19 (222% upside) at Noble Capital. More news on: electroCore, Inc., Sarepta Therapeutics, Inc., Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Sarepta a "Fresh Pick" at Baird in premarket analyst action

via: SeekingAlpha at 2019-05-09 04:16:53:000

ElectroCore (NASDAQ: ECOR ) initiated with Outperform rating and $19 (222% upside) at Noble Capital. More news on: electroCore, Inc., Sarepta Therapeutics, Inc., Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 18:33:11:000

Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Conference Call May 8, 2019, 04:30 PM ET Company Participants Scott Young - VP Corporate Communications and IR Mike Clayman - CEO and Co-Founder David Arkowitz - CFO Conference Call Participants David Maris - Wells Fargo Se… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 18:33:11:000

Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Conference Call May 8, 2019, 04:30 PM ET Company Participants Scott Young - VP Corporate Communications and IR Mike Clayman - CEO and Co-Founder David Arkowitz - CFO Conference Call Participants David Maris - Wells Fargo Se… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 18:33:11:000

Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Conference Call May 8, 2019, 04:30 PM ET Company Participants Scott Young - VP Corporate Communications and IR Mike Clayman - CEO and Co-Founder David Arkowitz - CFO Conference Call Participants David Maris - Wells Fargo Se… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 18:33:11:000

Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Conference Call May 8, 2019, 04:30 PM ET Company Participants Scott Young - VP Corporate Communications and IR Mike Clayman - CEO and Co-Founder David Arkowitz - CFO Conference Call Participants David Maris - Wells Fargo Se… read more...

Flexion Therapeutics EPS in-line, misses on revenue

via: SeekingAlpha at 2019-05-08 12:14:49:000

Flexion Therapeutics (NASDAQ: FLXN ): Q1 GAAP EPS of -$1.09 in-line. Revenue of $10.6M (+384.0% Y/Y) misses by $0.39M . Shares +2.9% . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

Flexion Therapeutics: A Second (And More) Life For Zilretta

via: SeekingAlpha at 2019-04-22 22:59:58:000

Flexion Therapeutics ( FLXN ) got approval for Zilretta last year for osteoarthritis of the knee or OAK. Zilretta is the first extended-release corticosteroid approved by the FDA for the indication. Effective January 1, 2019, Zilretta has been assigned a separate reimbursement code called the … read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

BTE, BRSS, WVE and FLXN among notable midday movers

via: SeekingAlpha at 2019-04-10 08:52:04:000

Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Disney+ And Bank Majors Step Out

via: SeekingAlpha at 2019-04-06 04:39:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-28 17:21:12:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Com… read more...

Flexion Therapeutics beats by $0.16, beats on revenue

via: SeekingAlpha at 2019-02-28 16:12:23:000

Flexion Therapeutics (NASDAQ: FLXN ): FY GAAP EPS of -$4.49 beats by $0.16 . Revenue of $22.5M beats by $0.2M . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

Flexion: Time To Join The Dance

via: SeekingAlpha at 2019-02-18 18:36:12:000

Flexion ( FLXN ) is in the process of establishing itself as a reliable revenue generator. I have been attracted to its potential and have been watching it for over a year. It is coming along nicely. I have been holding back on starting a position until it worked out kinks inherent in launchin… read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

Late-stage study shows favorable safety profile for Flexion's Zilretta

via: SeekingAlpha at 2019-02-11 16:45:28:000

Results from an open-label Phase 3b clinical trial evaluating repeat injections of Flexion Therapeutics' (NASDAQ: FLXN )ZILRETTA (triamcinolone acetonide extended-release injectable solution)in patients with knee osteoarthritis showed that it was generally safe and well-tolera… read more...

Late-stage study shows favorable safety profile for Flexion's Zilretta

via: SeekingAlpha at 2019-02-11 16:45:28:000

Results from an open-label Phase 3b clinical trial evaluating repeat injections of Flexion Therapeutics' (NASDAQ: FLXN )ZILRETTA (triamcinolone acetonide extended-release injectable solution)in patients with knee osteoarthritis showed that it was generally safe and well-tolera… read more...

Late-stage study shows favorable safety profile for Flexion's Zilretta

via: SeekingAlpha at 2019-02-11 16:45:28:000

Results from an open-label Phase 3b clinical trial evaluating repeat injections of Flexion Therapeutics' (NASDAQ: FLXN )ZILRETTA (triamcinolone acetonide extended-release injectable solution)in patients with knee osteoarthritis showed that it was generally safe and well-tolera… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

via: SeekingAlpha at 2019-01-08 11:35:38:000

Flexion Therapeutics, Inc. (FLXN) recently announced their unaudited Q4 revenue of $9.5M and their full-year revenue of approximately $22.5M. In addition, the company expects ZILRETTA to rake in $65-80M revenue in 2019. The share price dropped about 20% upon release but recovered following the… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-01-04 12:24:06:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Results Earnings Conference Call January 04, 2019, 08:30 AM ET Executives Scott Young - VP of Corporate Communications & IR Michael Clayman - Co-Founder, President, CEO & Director David Arkowitz - CFO Dan Deardorf - SVP of Comm… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-01-04 12:24:06:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Results Earnings Conference Call January 04, 2019, 08:30 AM ET Executives Scott Young - VP of Corporate Communications & IR Michael Clayman - Co-Founder, President, CEO & Director David Arkowitz - CFO Dan Deardorf - SVP of Comm… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-01-04 12:24:06:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Results Earnings Conference Call January 04, 2019, 08:30 AM ET Executives Scott Young - VP of Corporate Communications & IR Michael Clayman - Co-Founder, President, CEO & Director David Arkowitz - CFO Dan Deardorf - SVP of Comm… read more...

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-01-04 12:24:06:000

Flexion Therapeutics, Inc. (FLXN) Q4 2018 Results Earnings Conference Call January 04, 2019, 08:30 AM ET Executives Scott Young - VP of Corporate Communications & IR Michael Clayman - Co-Founder, President, CEO & Director David Arkowitz - CFO Dan Deardorf - SVP of Comm… read more...

Flexion Therapeutics reports preliminary Q4 results

via: SeekingAlpha at 2019-01-03 16:10:01:000

Flexion Therapeutics (NASDAQ: FLXN ): expects Q4 revenue of$9.5M (+36% Y/Y) vs. a consensus of $10.16M. More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook

via: SeekingAlpha at 2019-01-03 16:08:13:000

On a preliminary basis, Flexion Therapeutics (NASDAQ: FLXN ) generated $9.5M in revenue in Q4, up 36% yoy. Full-year revenue was ~$22.5M. More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Late-stage study commences for Flexion's Zilretta in hip osteoarthritis

via: SeekingAlpha at 2019-01-02 16:54:32:000

Enrollment is underway in a Phase 3 clinical trial evaluating Flexion Therapeutics' (NASDAQ: FLXN ) ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with hip osteoarthritis, a degenerative condition that strikes up to 25% of Americans in their l… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Perception Vs. Reality

via: SeekingAlpha at 2018-12-03 11:13:12:000

Living with a loss is folly, taking a loss is wisdom. . . . Lewis Owen For years we have quoted Benjamin Graham's book, The Intelligent Investor, which Warren Buffet has said is the best book ever written on investing. The operative quote from said book is "The essence of portfolio manag… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon

via: SeekingAlpha at 2018-11-13 13:23:49:000

With one product candidate at Phase 3 of development, a large amount of cash and a solid balance sheet, Centrexion Therapeutics ( CNTX ) may attract the attention of certain institutional investors. With that, a detailed assessment of the competitors shows that there are many companies that ar… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion Therapeutics: Reversal In Sentiment?

via: SeekingAlpha at 2018-11-09 14:39:25:000

We no longer live life. We consume it ." - Vicki Robin Insiders and Biotech Forum model portfolio holding Flexion Therapeutics ( FLXN ) was one of the markets big winners in the market on Thursday. The almost 20% rise in the stock was triggered by better than expected Q3 results and som… read more...

Flexion up 19% after Q3 beat, Zilretta commercial progress

via: SeekingAlpha at 2018-11-08 11:21:50:000

Flexion Therapeutics ( FLXN +18.7% ) is up on average volume following its Q3 report released after the close yesterday. Highlights: More news on: Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 21:26:13:000

Flexion Therapeutics Inc. (FLXN) Q3 2018 Earnings Conference Call November 7, 2018 4:30 PM ET Executives Scott Young Vice President-Corporate Communications and Investor Relations Michael Clayman Chief Executive Officer Dan Deardorf Senior Vice Preside… read more...

Flexion Therapeutics beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-07 16:25:42:000

Flexion Therapeutics (NASDAQ: FLXN ): Q3 GAAP EPS of -$1.15 beats by $0.04 . Revenue of $7M beats by $0.3M . Shares -2.1% . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Centrexion Therapeutics Seeks $75 Million In Proposed IPO

via: SeekingAlpha at 2018-11-05 13:56:42:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...

Centrexion Therapeutics Seeks $75 Million In Proposed IPO

via: SeekingAlpha at 2018-11-05 13:56:42:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Centrexion Therapeutics Begins U.S. IPO Effort

via: SeekingAlpha at 2018-10-25 16:11:14:000

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Flexion Is Flexible With The Data, Rigid With The Price

via: SeekingAlpha at 2018-10-17 09:30:00:000

Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexions only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&… read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Axsome Therapeutics: Several Candidates At Phase 3

via: SeekingAlpha at 2018-10-11 12:11:55:000

With several candidates at Phase 3 of development, Axsome Therapeutics, Inc. (AXSM) should interest investors. In addition, the target market seems quite large, which is also ideal. With that, the company trades at an overvalued 10x book value per share, which seems like an overvalued level … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-09-06 15:11:12:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Gene therapy players under pressure

via: SeekingAlpha at 2018-09-05 10:58:30:000

The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

Flexion: Waiting And Watching

via: SeekingAlpha at 2018-08-22 05:22:24:000

This posting focuses on Flexion Therapeutics' (FLXN) Zilretta launch as a therapy for osteoarthritis knee pain , now exiting its second full post-launch quarter. I conclude that Zilretta is likely to continue to be more of a financial burden than a contributor for the balance of 2018. Accordi… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

FDA and NIH to loosen oversight of gene therapy development

via: SeekingAlpha at 2018-08-16 09:47:09:000

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 22:21:11:000

Flexion Therapeutics Inc. (FLXN) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET Executives Scott Young Vice President for Corporate Communications and Investor Relations Michael Clayman Chief Executive Officer Dan Deardorf Senior Vice Presid… read more...

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 22:21:11:000

Flexion Therapeutics Inc. (FLXN) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET Executives Scott Young Vice President for Corporate Communications and Investor Relations Michael Clayman Chief Executive Officer Dan Deardorf Senior Vice Presid… read more...

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 22:21:11:000

Flexion Therapeutics Inc. (FLXN) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET Executives Scott Young Vice President for Corporate Communications and Investor Relations Michael Clayman Chief Executive Officer Dan Deardorf Senior Vice Presid… read more...

Flexion Therapeutics beats by $0.07, misses on revenue

via: SeekingAlpha at 2018-08-07 16:05:20:000

Flexion Therapeutics (NASDAQ: FLXN ): Q2 EPS of -$1.16 beats by $0.07 . Revenue of $3.8M misses by $0.46M . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Gene therapy players in the green

via: SeekingAlpha at 2018-06-20 14:27:32:000

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Gene therapy players in the green

via: SeekingAlpha at 2018-06-20 14:27:32:000

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Gene therapy players in the green

via: SeekingAlpha at 2018-06-20 14:27:32:000

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Gene therapy players in the green

via: SeekingAlpha at 2018-06-20 14:27:32:000

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

via: PR Newswire at 2018-06-13 09:00:00:000

DURHAM, North Carolina , June 13, 2018 /PRNewswire/ -- Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services p… read more...

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

via: PR Newswire at 2018-06-13 09:00:00:000

DURHAM, North Carolina , June 13, 2018 /PRNewswire/ -- Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services p… read more...

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

via: PR Newswire at 2018-06-13 09:00:00:000

DURHAM, North Carolina , June 13, 2018 /PRNewswire/ -- Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services p… read more...

Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-08 22:46:15:000

Flexion Therapeutics, Inc. (FLXN) Q1 2018 Earnings Conference Call May 08, 2018, 04:30 PM ET Executives David Arkowitz - CFO Dan Deardorf - SVP of Commercial Michael Clayman - Co-Founder, President, CEO Scott Young - VP of Corporate Communications & IR Analysts Dan Bu… read more...

Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-08 22:46:15:000

Flexion Therapeutics, Inc. (FLXN) Q1 2018 Earnings Conference Call May 08, 2018, 04:30 PM ET Executives David Arkowitz - CFO Dan Deardorf - SVP of Commercial Michael Clayman - Co-Founder, President, CEO Scott Young - VP of Corporate Communications & IR Analysts Dan Bu… read more...

Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-08 22:46:15:000

Flexion Therapeutics, Inc. (FLXN) Q1 2018 Earnings Conference Call May 08, 2018, 04:30 PM ET Executives David Arkowitz - CFO Dan Deardorf - SVP of Commercial Michael Clayman - Co-Founder, President, CEO Scott Young - VP of Corporate Communications & IR Analysts Dan Bu… read more...

Flexion Therapeutics beats by $0.23, misses on revenue

via: SeekingAlpha at 2018-05-08 16:05:08:000

Flexion Therapeutics (NASDAQ: FLXN ): Q1 EPS of -$1.10 beats by $0.23 . More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Flexion Therapeutics beats by $0.23, misses on revenue

via: SeekingAlpha at 2018-05-08 16:05:08:000

Flexion Therapeutics (NASDAQ: FLXN ): Q1 EPS of -$1.10 beats by $0.23 . More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Flexion Therapeutics beats by $0.23, misses on revenue

via: SeekingAlpha at 2018-05-08 16:05:08:000

Flexion Therapeutics (NASDAQ: FLXN ): Q1 EPS of -$1.10 beats by $0.23 . More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Permanent reimbursement for Flexion's Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

Permanent reimbursement for Flexion's Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

Permanent reimbursement for Flexion's Zilretta established in U.S.

via: SeekingAlpha at 2018-05-04 08:15:58:000

Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

2 Attractive Biotech Stocks To Buy Now

via: SeekingAlpha at 2018-05-02 10:25:19:000

T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss . Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w… read more...

Flexion up 2% on new Zilretta data in OAK

via: SeekingAlpha at 2018-04-26 11:12:09:000

Flexion Therapeutics ( FLXN +2.3% ) is up, albeit on light volume, on the heels of its announcement of additional data from the open-label Phase 3b study evaluating ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK). The results will be presented tomorro… read more...

Flexion up 2% on new Zilretta data in OAK

via: SeekingAlpha at 2018-04-26 11:12:09:000

Flexion Therapeutics ( FLXN +2.3% ) is up, albeit on light volume, on the heels of its announcement of additional data from the open-label Phase 3b study evaluating ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK). The results will be presented tomorro… read more...

Novartis takeout of AveXis stokes buying in gene therapy players

via: SeekingAlpha at 2018-04-09 07:19:12:000

Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up 8% and 10% premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In… read more...

Novartis takeout of AveXis stokes buying in gene therapy players

via: SeekingAlpha at 2018-04-09 07:19:12:000

Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up 8% and 10% premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In… read more...

Flexion Therapeutics (FLXN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:56:56:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:56:56:000

The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with this Read more … read more...

Flexion Therapeutics (FLXN) CEO Mike Clayman on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-09 05:12:02:000

Flexion Therapeutics, Inc. (FLXN) Q4 2017 Earnings Conference Call March 8, 2018 04:30 p.m. ET Executives Mike Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President of Commercial Operations Scott Young - Vice President for Corporate Communications, Investor Relat… read more...

Flexion Therapeutics (FLXN) CEO Mike Clayman on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-09 05:12:02:000

Flexion Therapeutics, Inc. (FLXN) Q4 2017 Earnings Conference Call March 8, 2018 04:30 p.m. ET Executives Mike Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President of Commercial Operations Scott Young - Vice President for Corporate Communications, Investor Relat… read more...

Flexion Therapeutics misses by $0.35, misses on revenue

via: SeekingAlpha at 2018-03-08 16:03:13:000

Flexion Therapeutics (NASDAQ: FLXN ): FY EPS of -$4.16 misses by $0.35 . Revenue of $0.36M misses by $0.22M . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Flexion Therapeutics misses by $0.35, misses on revenue

via: SeekingAlpha at 2018-03-08 16:03:13:000

Flexion Therapeutics (NASDAQ: FLXN ): FY EPS of -$4.16 misses by $0.35 . Revenue of $0.36M misses by $0.22M . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-03-02 11:03:10:000

Noteworthy events for the week of March 4 - 10 for healthcare investors: More news on: Merck & Co Inc., Arena Pharmaceuticals, Inc., NeuroMetrix, Inc., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-03-02 11:03:10:000

Noteworthy events for the week of March 4 - 10 for healthcare investors: More news on: Merck & Co Inc., Arena Pharmaceuticals, Inc., NeuroMetrix, Inc., Healthcare stocks news, Read more … read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

2 Small Biotechs To Buy On This Dip

via: SeekingAlpha at 2018-02-08 16:14:50:000

Those who make conversations impossible, make escalation inevitable . Stefan Molyneux It has been a wild wide so far for investors so far in the month of February. Each day of the month seem to have triggered huge intra-day swings within equities. Stocks have given up mo… read more...

Solid Biosciences slips

via: SeekingAlpha at 2018-01-30 12:10:06:000

Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...

Solid Biosciences slips

via: SeekingAlpha at 2018-01-30 12:10:06:000

Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...

Solid Biosciences slips

via: SeekingAlpha at 2018-01-30 12:10:06:000

Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...

Flexion: Ready To Rumble (Almost)

via: SeekingAlpha at 2018-01-11 05:29:44:000

Flexion ( FLXN ) offers relief to weary folks whose knees are killing them. Its stock is poised to do the same for its investors' portfolios; there is just one key detail needing resolution. Investors interested in the Flexion story need to hold back until they get some clarity on this one iss… read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Flexion's Zilretta shows treatment benefit in late-stage OAK study evaluating second injection

via: SeekingAlpha at 2018-01-08 07:55:13:000

Preliminary data from a Phase 3b open-label study assessing the repeat administration of Flexion Therapeutics' (NASDAQ: FLXN ) ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK) showed 95% (n=195/205) experienced clinical benefit by week 12 after the init… read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

pSivida's Encouraging Knee Osteoarthritis Data

via: SeekingAlpha at 2017-12-15 13:48:28:000

pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company specializing in sustained release drug delivery products for diseases of the eye, recently released promising data from their knee osteoarthritis ((OA)) Phase 1 trial. This is highly encouraging, as it proves that the company's … read more...

Flexion nabs rights to non-opioid med for knee arthritis pain

via: SeekingAlpha at 2017-12-13 16:26:05:000

Flexion Therapeutics (NASDAQ: FLXN ) inks an agreement with Hamburg, Germany-based GeneQuine Biotherapeutics GmbH for exclusive global rights to GQ-203 (renamed FX201), a non-opioid, intra-articular therapeutic for the relief of knee pain and disease modification in patients with knee … read more...

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

via: SeekingAlpha at 2017-11-12 00:20:46:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Neurocrine Biosciences Today we will d… read more...

Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-06 20:46:10:000

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Q3 2017 Earnings Conference Call November 6, 2017 4:30 AM ET Executives Scott Young - Vice President-Medical Affairs Mike Clayman - CEO and Co-Founder Dan Deardorf - SVP-Commercial Fred Driscoll - CFO Analysts David Maris - Wells F… read more...

Flexion Therapeutics misses by $0.09

via: SeekingAlpha at 2017-11-06 16:07:12:000

Flexion Therapeutics (NASDAQ: FLXN ): Q3 EPS of -$1.07 misses by $0.09 . Cash and equivalents of $159.2M. Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Biotech Forum Daily Digest: Possible Buyout Scenarios For Neos Therapeutics

via: SeekingAlpha at 2017-10-31 09:50:18:000

Solitude is fine but you need someone to tell that solitude is fine . - Honore De Balzac The biotech sector Monday added slightly to its gains from Friday after last week's decline on poor earning results from industry stalwarts like Celgene ( CELG ) . Once again small caps in th… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud